RGEN
NASDAQRepligen Corporation
News · 26 weeks55-8%
2025-12-142026-06-07
Mix3290d
- Insider15(47%)
- SEC Filings7(22%)
- Other5(16%)
- Analyst3(9%)
- Earnings2(6%)
Latest news
25 items- ANALYSTWolfe Research resumed coverage on Repligen with a new price targetWolfe Research resumed coverage of Repligen with a rating of Outperform and set a new price target of $145.00
- PRRepligen Corporation to Present at William Blair 46th Annual Growth Stock ConferenceWALTHAM, Mass., May 22, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the William Blair 46th Annual Growth Stock Conference in Chicago, IL. Olivier Loeillot, President and Chief Executive Officer, will present a company overview on June 3rd at 10:40 a.m. CT. A live webcast of the conference presentation will be accessible through Repligen's Investor Relations website at www.repligen.com, and will be available for replay for a limited period of time following the event. About Repligen Corporation Repligen Corporation is a global life sciences company that de
- PRRepligen Announces Publication of the Company's 2025 Corporate Sustainability ReportWALTHAM, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of its 2025 Corporate Sustainability Report and related reporting framework disclosures. Themed "Driving Sustainable Growth Together", this report communicates the company's progress in advancing our sustainability strategy across six key impact areas: Products & Packaging, Operations, Talent, Supply Chain, Communities, and Pathways to Success. Also included in the 2025 Sustainability Report are detailed disclosures aligned with the United Nations Sustainable Development Goals (UN SDGs) and three
- INSIDERDirector Pax Margaret was granted 995 shares, increasing direct ownership by 49% to 3,011 units (SEC Form 4)4 - REPLIGEN CORP (0000730272) (Issuer)
- INSIDERDirector Eglinton Manner Carrie was granted 995 shares, increasing direct ownership by 22% to 5,461 units (SEC Form 4)4 - REPLIGEN CORP (0000730272) (Issuer)
- INSIDERDirector Mhatre Rohin was granted 995 shares, increasing direct ownership by 25% to 5,014 units (SEC Form 4)4 - REPLIGEN CORP (0000730272) (Issuer)
- INSIDERDirector Madaus Martin D was granted 995 shares, increasing direct ownership by 18% to 6,581 units (SEC Form 4)4 - REPLIGEN CORP (0000730272) (Issuer)
- INSIDERDirector Konstantinov Konstantin was granted 995 shares, increasing direct ownership by 34% to 3,889 units (SEC Form 4)4 - REPLIGEN CORP (0000730272) (Issuer)
- INSIDERDirector Dawes Karen A was granted 995 shares, increasing direct ownership by 1% to 92,816 units (SEC Form 4)4 - REPLIGEN CORP (0000730272) (Issuer)
- INSIDERDirector Barthelemy Nicolas was granted 995 shares, increasing direct ownership by 22% to 5,436 units (SEC Form 4)4 - REPLIGEN CORP (0000730272) (Issuer)
- INSIDERDirector Muir Glenn P was granted 995 shares, increasing direct ownership by 3% to 40,051 units (SEC Form 4)4 - REPLIGEN CORP (0000730272) (Issuer)
- ANALYSTRBC Capital Mkts resumed coverage on Repligen with a new price targetRBC Capital Mkts resumed coverage of Repligen with a rating of Outperform and set a new price target of $160.00
- SECRepligen Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - REPLIGEN CORP (0000730272) (Filer)
- INSIDERDirector Muir Glenn P exercised 2,434 shares at a strike of $38.76, increasing direct ownership by 7% to 39,056 units (SEC Form 4)4 - REPLIGEN CORP (0000730272) (Issuer)
- INSIDERCHIEF PRODUCT OFFICER Douglass Brian Robb covered exercise/tax liability with 334 shares, decreasing direct ownership by 4% to 7,985 units (SEC Form 4) to satisfy withholding obligation4 - REPLIGEN CORP (0000730272) (Issuer)
- PRRepligen Corporation to Present at Bank of America Securities 2026 Global Healthcare ConferenceWALTHAM, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the Bank of America Securities 2026 Global Healthcare Conference, being held May 12-14 in Las Vegas, Nevada. Jason Garland, Chief Financial Officer, will participate in an analyst-led discussion on May 12 at 10:00am PT. A live webcast of the conference presentation will be accessible through Repligen's Investor Relations website at www.repligen.com, and will be available for replay for a limited period of time following the event. About Repligen Corporation Repligen Corporation is a globa
- SECSEC Form 10-Q filed by Repligen Corporation10-Q - REPLIGEN CORP (0000730272) (Filer)
- SECRepligen Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - REPLIGEN CORP (0000730272) (Filer)
- PRRepligen Reports First Quarter 2026 Financial Results and Updates Full Year 2026 Financial GuidanceFirst quarter revenue of $194 million, a year-over-year increase of 15% as reported and 11% organicGAAP EPS increased 50% year-over-year and adjusted EPS increased 23% year-over-yearReiterating FY26 organic revenue growth guidance of 9%-13% and increasing adjusted EPS to $1.97-$2.05 WALTHAM, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first quarter of 2026, covering the three-month period ended March 31, 2026. The Company is also providing updated financial guidance for the full year 2026. Olivier Loeillot, President and Chief Executive Officer
- SECSEC Form DEFA14A filed by Repligen CorporationDEFA14A - REPLIGEN CORP (0000730272) (Filer)
- INSIDERSEC Form 4 filed by Loeillot Olivier4 - REPLIGEN CORP (0000730272) (Issuer)
- PRRepligen to Report First Quarter 2026 Financial ResultsWALTHAM, Mass., April 22, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2026 financial results on Tuesday, May 5, 2026. The Company will issue a press release before the market opens and will host a conference call at 8:00 a.m. ET to discuss business updates and financial results for the three-month reporting period ended March 31, 2026. The conference call will be accessible by dialing toll-free (833) 461-5787 for domestic callers and (585) 542-9983 for international callers. The meeting ID is: 931163466. In addition, a webcast will be accessible via the Investor Relations section of the Company's website. The w
- SECSEC Form 144 filed by Repligen Corporation144 - REPLIGEN CORP (0000730272) (Subject)
- ANALYSTRothschild & Co Redburn initiated coverage on Repligen with a new price targetRothschild & Co Redburn initiated coverage of Repligen with a rating of Buy and set a new price target of $160.00
- PRRepligen Opens European Training & Innovation Center in Breda, Expanding Global Customer Support NetworkWALTHAM, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the grand opening of its new Repligen Training & Innovation Center ("RTIC") at its OPUS® Pre-packed Chromatography Columns manufacturing facility in Breda, the Netherlands. The RTIC buildout, which features product exhibits and purpose-built demonstration areas, was designed to provide customers with pre- and post-sales support, and a hands-on experience with Repligen's innovative bioprocessing solutions. The Breda RTIC is Repligen's third global training and innovation center, joining existing locations in Waltham,
RGEN FAQ
7 questionsWhat does Repligen Corporation do?
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance...Where does RGEN stock trade?
Repligen Corporation (RGEN) is listed on NASDAQ.What sector and industry is RGEN in?
Repligen Corporation operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Repligen Corporation go public?
Repligen Corporation (RGEN) completed its IPO in 1986.What are analysts saying about RGEN?
Repligen Corporation has had 8 recent analyst actions on file. The most recent action was from Wolfe Research: Outperform on 2026-06-02.What companies are similar to RGEN?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare RGEN side-by-side with any of them on Quantisnow.How can I track RGEN on Quantisnow?
Quantisnow aggregates Repligen Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow RGEN to receive live email and push alerts on every new disclosure.